We are removing GALP from our ODDO BHF European Large Caps list. The stock has chalked up a performance of +31.3% since its inclusion in the list on 20 March. Our analyst is adopting today a Neutral recommendation (vs Outperform) on the stock. - ...
>Q1 review – Strong beat on bottom line - GN Store Nord achieved Q1 revenues of DKK 4,303m (+2.1% y-o-y, 0%/+1% vs ODDO BHF/consensus). Q1 adj. EBITA reached DKK 538m (+218% y-o-y, margin 12.5%), which was a strong beat by 35% of our estimates and by 32% vs consensus. EPS reached DKK 1.74 (vs DKK 0.87/0.85 expected). The 2024 guidance is confirmed.GN Hearing - Excellent organic growth on new Nexia platform - GN Hearing’s Q1 revenues of DKK 1,737m (+7....
Interim Report Q1 2024: GN Store Nord delivered organic revenue growth of 5% reaching an EBITA margin of 12.5% Highlights GN delivered continued execution across the three divisions resulting in 5% organic revenue growth for the GroupThe Hearing division delivered continued market share gains leading to 14% organic revenue growth, resulting in 8.2 percentage point increase in the divisional profit margin supported by synergies and a successful ReSound Nexia roll-outThe Enterprise division continued its relentless commercial execution in a stabilizing market leading to 0% organic revenue gr...
We forecast Q1 organic revenue growth of 4.7% YOY (in line with consensus), driven by Hearing Care (we forecast 4.9%) and Diagnostics (we forecast 8.4%), while Hearing Aids faces a tough YOY comparable (we forecast 3.6%). We expect 2024 to be back-end loaded and driven by Oticon Intent. We expect maintained 2024 guidance of 4–8% organic growth, c1% M&A growth, c-1% FX, and EBIT of DKK4.6bn–5.0bn. We reiterate our BUY and DKK400 target price.
We forecast Q1 organic sales growth of 3.0% YOY (consensus 2.8%) and an EBITA margin of 9.7% (consensus 9.6%). We see Hearing as starting well, and despite still-negative growth in Enterprise, we expect unchanged 2024 guidance. The upcoming CMD offers management scope to rebuild credibility, and we expect updated long-term targets to reflect “One-GN”. We reiterate our BUY and have raised our target price to DKK230 (215).
Annual General Meeting 2024 – GN Store Nord A/S Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 19, 2024, as set out below. The report by the Board of Directors was noted by the general meeting. The Annual Report 2023 and the proposal on distribution of annual profits, including no distribution of dividends, were approved, and discharge was granted to the Board of Directors and the Executive Management. The general meeting approved the remuneration to the Board of Directors for 2024, ...
At its CMD, Demant updated its long-term outlook. It now targets 8–10% LCY growth (7–10%) including 6–8%-points organic growth and c2%-points M&A growth, and still sees incremental EBIT margin expansion. It expects the hearing-aid market to grow 4–6% p.a. in value (2–5%), as ASP is now guided fairly flat. We are positive on the Sirius-based Oticon Intent launch. We reiterate our BUY, and have raised our target price to DKK400 (375).
>GN Hearing with strong year ahead - On the back of the recently launched Resound Nexia hearing aid platform, we expect the market share gains to continue. The expansion of the portfolio with new ITE and BTE form factors should underscore our new expected organic growth of 9.0% for 2024 (guidance 8% to 12%). Hence, we see the company well on track to achieve its EBITA margin guidance of 18% to 20% for the core hearing aids business, which compares to our new forecast ...
GN Store Nord A/S - Notice to convene the Annual General Meeting 2024 GN Store Nord’s Annual General Meeting will be held on Wednesday, March 13, 2024, at 10:00 a.m. CET at the company’s address: Lautrupbjerg 7, 2750 Ballerup, Denmark. Please find attached the notice to convene the Annual General Meeting, including the agenda and complete proposals. For further information, please contact: Investor RelationsRune Sandager Media Relations Steen Frentz Laursen About GN GN facilitates communication between people through intelligent hearing, audio, video, and gaming ...
>Strong performance to continue - Demant’s Q4 results showed, with an organic growth of 10%, a continuation of the strong performance of previous quarters. On the back of the announced launch of the new hearing aid platform Oticon Intega, we expect that the market share gains in the hearing aid segment will continue also in 2024. Our organic growth forecast for 2024 stands at 7.4% (guidance 4-8%) for the company driven by an expected 8.0% for the hearing aid wholesale...
Q4 saw improved underlying market trends, with organic revenue in line with our expectation while profitability missed primarily due to one-offs. Momentum into 2024 gives a solid guidance for organic revenue growth of 2–8%, split between 8–12% for GN Hearing, -3 to +5% for Enterprise and 2–10% for Gaming & Consumer. The EBITA margin guidance is 12–14%, with 18–20% for GN Hearing Core but not specified for the two other divisions. We reiterate our BUY and DKK215 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.